Telix adds Pixclara momentum to strong Q3 growth and ITM merger

Precision Medicine drives third-quarter growth

Telix Pharmaceuticals Limited (ASX:TLX, NASDAQ: TLX) delivered US$245 million in unaudited group revenue for the September quarter, up 19% from the same period last year. The result was broadly stable against the June quarter, when revenue reached US$247 million, but the company said stronger September sales lifted its quarterly exit rate.

The main engine remained Precision Medicine, where revenue rose 30% year on year to US$201 million. Telix said demand for Gozellix and Illuccix remained strong, with US dose volumes increasing 1% from the previous quarter despite expected summer seasonality. TMS revenue, by contrast, fell 6% year on year to US$44 million.

That commercial performance gives Telix a larger base from which to launch new products. FDA-approved Pixclara, which became the first approved imaging agent for glioma in the United States, saw its first commercial doses administered in September. The company is also advancing a Phase 3 study that could support an expanded label for brain metastases imaging, while its European application for Pixlumi remains under review. The earlier Pixclara FDA approval had been described as commercially significant, although pricing, reimbursement and launch timing were not disclosed.

BiPASS reaches the regulatory handoff

Telix has completed enrolment of 350 patients in BiPASS, its Phase 3 study of 68Ga-PSMA-11 PET combined with MRI before prostate biopsy. The FDA has supported an NDA pathway and granted Fast Track designation, potentially allowing an expedited review, but the announcement does not provide efficacy results from the trial.

The development moves the program from recruitment to the regulatory preparation stage. Telix said BiPASS is intended to support submissions for the pre-biopsy use of its PSMA imaging products, building on earlier PRIMARY studies. The completed BiPASS enrolment was previously reported alongside the FDA-aligned NDA pathway, while the indication remains investigational until any approval is granted.

ITM merger adds scale and transaction risk

The largest strategic item in the update is Telix's proposed merger with Isotope Technologies Munich SE. The transaction carries upfront consideration of US$1.65 billion on a cash-free, debt-free basis, including approximately US$1.25 billion in Telix shares issued as American depositary receipts to ITM shareholders. Up to a further US$700 million could become payable if specified regulatory and commercial milestones for ITM-11 are achieved.

Telix says ITM would add a late-stage therapeutic asset in ITM-11, aimed at gastroenteropancreatic neuroendocrine tumours, alongside expanded isotope production and manufacturing capabilities. The deal remains conditional on Telix shareholder approval and other customary closing conditions, with a general meeting expected on December 1. The proposed ITM merger has already been framed as a way to strengthen supply-chain control and broaden Telix's therapeutic platform, but the share component also means dilution and integration remain central considerations.

Guidance holds as pipeline spending is reset

Telix reaffirmed that FY 2026 revenue and other income should exceed US$1 billion. Revenue is tracking towards the upper end of its US$950 million to US$970 million guidance range, with US$40 million of other reported income included in the broader target. The company also expects Precision Medicine revenue growth of more than 25% for the full year.

R&D expenditure guidance was narrowed to US$240 million to US$260 million, from a previous range of US$230 million to US$270 million. The filing provides no new quarterly profit, cash-flow or balance-sheet figures, leaving the financial effect of the ITM transaction and the cost of the expanding development portfolio unresolved.

Several pipeline catalysts sit ahead: a potential FDA submission supporting the next stage of the ProstACT Global Phase 3 study, a first-half 2027 readout from the 120-patient OPTIMAL-PSMA study, continued enrolment in LUTEON and progress towards regulatory submissions in Japan and the United States. Telix is also preparing a resubmission for Zircaix after a corrected FDA complete response letter, making execution across commercial launches, manufacturing and regulation as important as the headline revenue growth.